Latest News

  • 25th June 2020

    Arecor featured in New Scientist’s Business and Industry 2020 Life Sciences campaign – bringing effective and affordable drugs to market more quickly

  • 15th June 2020

    Arecor presents positive results for the first phase I clinical trial of AT247, a novel ultra-rapid acting insulin

  • 10th June 2020

    Arecor announces oral presentation of the first phase I clinical trial of AT247, a novel ultra rapid acting formulation of insulin, at the ADA 80th scientific sessions

News

Reset
  • 25/06/2020

    Arecor featured in New Scientist’s Business and Industry 2020 Life Sciences campaign – bringing effective and affordable drugs to market more quickly

  • 15/06/2020

    Arecor presents positive results for the first phase I clinical trial of AT247, a novel ultra-rapid acting insulin

  • 10/06/2020

    Arecor announces oral presentation of the first phase I clinical trial of AT247, a novel ultra rapid acting formulation of insulin, at the ADA 80th scientific sessions

  • 09/06/2020

    Arecor announces launch of new website

  • 19/03/2020

    Arecor extends multi-product collaboration with clinical stage biotech

  • 25/02/2020

    Arecor achieves second license milestone payment from global pharmaceutical partner

  • 13/02/2020

    Arecor signs a new feasibility study agreement with top five pharma company

  • 16/01/2020

    Arecor to participate at PEPTalk 2020’s Protein Science week in San Diego, CA, USA

  • 09/01/2020

    Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology